MedTrace Logo

Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis

NCT06466421 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-27

No results posted yet for this study

Summary

Several studies investigated the effectiveness of Gabapentin in Uremic Pruritus (UP). No previous studies investigated the use of fexofenadine in UP. The aim of this trial is to assess the safety and possible efficacy of fexofenadine in patients with UP.

Conditions

  • Uremic Pruritus
  • Chronic Kidney Disease-associated Pruritus
  • Hemodialysis
  • End-stage Renal Disease
  • Renal Replacement Therapy
  • ESRD

Interventions

DRUG

Fexofenadine

Fexofenadine 60 mg orally once daily for 3 months

DRUG

Gabapentin

100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sahar M El-Haggar, PhD · Tanta University

  • Ahmed M Hussein, PhD · Helwan University

  • Mohamed I Hosney, PharmD · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2024-10-01
Completion
2024-12-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06466421 on ClinicalTrials.gov